Table 4.

Proportion of 61 HIV-infected infants starting antiretroviral therapy (ART) within 14 days of birth surviving in follow-up who met more stringent virologic endpoints by age at ART initiation.

Characteristic	Total			Initiated ART <48 h			Initiated ART 2 to 14 days			p-value
	N	% of 61 in follow-up (95% CI)	n/N (%) in sub-group	N	% of 35 in follow-up (95% CI)	n/N (%) in sub-group	N	% of 26 in follow-up (95% CI)	n/N (%) in sub-group
Did not achieve “Target not detected” (TND) by 48 weeks	25	41.0		13	37.1		12	46.2
Achieved TND then any rebound	26	42.6		16	45.7		10	38.5
Sustained TND	10	16.4 (8.2–28.1)		6	17.1 (6.6–33.7)		4	11.1 (4.4–34.9)		1.000
Ever PCR negative	14	23.0 (13.2–35.5)		10	28.6 (14.6–46.3)		4	15.4 (4.4–34.9)		0.357
Non-transient PCR negative	9	14.8 (7.0–26.2)		6	17.1 (6.6–33.7)		3	11.5 (2.5–30.2)		0.720
Non-transient PCR negative in achieved & sustained <50 copies/ml group	9		9/32 (28.1)	6		6/18 (33.3)	3		3/14 (21.4)
Non-transient PCR negative in achieved & sustained TND group	5		5/10 (50.0)	4		4/6 (66.7)	1		1/4 (25.0)

Abbreviations: Antiretroviral treatment (ART), Confidence intervals (CI), Target not detected (TND), polymerase chain reaction (PCR).